Cargando…
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
The cyclin-dependent kinase 4/6 (CDK4/6) kinase is dysregulated in melanoma, highlighting it as a potential therapeutic target. CDK4/6 inhibitors are being evaluated in trials for melanoma and additional cancers. While beneficial, resistance to therapy is a concern, and the molecular mechanisms of s...
Autores principales: | Yoshida, Akihiro, Bu, Yiwen, Qie, Shuo, Wrangle, John, Camp, E. Ramsay, Hazard, E. Starr, Hardiman, Gary, de Leeuw, Renée, Knudsen, Karen E., Diehl, J. Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750908/ https://www.ncbi.nlm.nih.gov/pubmed/31555743 http://dx.doi.org/10.1126/sciadv.aax6352 |
Ejemplares similares
-
An mTORC1-to-CDK1 Switch Maintains Autophagy Suppression during Mitosis
por: Odle, Richard I., et al.
Publicado: (2020) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022) -
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018) -
Insights into the Interaction of Lysosomal Amino Acid Transporters SLC38A9 and SLC36A1 Involved in mTORC1 Signaling in C2C12 Cells
por: Wang, Dan, et al.
Publicado: (2021)